The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | CheckMate 722: Investigating the addition of immunotherapy to chemotherapy in EGFR-Mutant NSCLC
Tony Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong, discusses the Phase III CheckMate 722 trial (NCT02864251), which involved randomising patients who had failed on tyrosine receptor inhibitors (TKIs) onto nivolumab plus chemotherapy or chemotherapy alone. The difference between treatment group outcomes was found to be statistically insignificant, which has been corroborated by the Phase III KEYNOTE-789 trial (NCT03515837). Therefore, immunotherapy in addition to chemotherapy is not useful in these cases. A currently ongoing randomized trial aims to evaluate cabozantinib plus bevacizumab and atezolizumab, versus bevacizumab alone. The outcome of this trial will influence the next steps for the CheckMate-722 population. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
